You are here
Maximizing Clinical Management for Your Patients: Advances in Cancer Care with MKIs (AJ)
Sun 27 Sept. / 13:00 to 14:30 / Hall A4 /
Increased understanding of the molecular pathogenesis of cancer has led to development of several multikinase inhibitors (MKIs) designed to target specific molecular alterations and dysregulations of oncogenic pathways implicated in tumorigenesis. In the past decade, MKIs such as sorafenib, which targets vascular endothelial growth factor receptor–mediated tumor angiogenesis, have been approved for various tumor types, including renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). More recently, MKIs have also demonstrated efficacy in patients with differentiated thyroid cancer (DTC) who are refractory to radioactive iodine (RAI) therapy. Nevertheless, critical questions remain. Current gaps in the understanding of MKI treatment include optimal timing of treatment initiation, appropriate dosing and duration of treatment, and assessment of treatment response. Conventional tumor assessment criteria, such as Response Evaluation Criteria in Solid Tumors (RECIST), may not be sufficiently sensitive to determine treatment benefit from targeted therapies. Identifying a better approach to assess the effects of MKIs may help optimize treatment decisions and improve patient outcomes. Additionally, real-world data reveal discrepancies between treatment guidelines and daily practice, indicating the need to provide education and standardize treatment practices according to evidence-based clinical practice guidelines. (G.MKT.SM.ON.10.2015.1453)
Speaker and Chair: Markus Peck-Radosavljevic, MD (Austria)Associate Professor of Medicine Vice Chair, Department of Gastroenterology & Hepatology Medizinische Universität Wien Vienna, Austria
Speaker: Bruno Daniele MD, PhD (Italy)Director, Department of Oncology and Medical Oncology Unit G. Rummo Hospital Benevento, Italy Professor, Department of Oncology Postgraduate School of...
Speaker: Marcia Simpson Brose, MD, PhD (USA)Director of the Thyroid Cancer Therapeutics Program Department of Otorhinolaryngology: Head and Neck Surgery and Department of Medicine, Division of...
Speaker: Rodolfo Sacco MD, PhD (Italy)Head, Hepatocellular Carcinoma Outpatient Section Department of Gastroenterology Cisanello Pisa University Hospital Pisa, Italy
M. Peck-Radosavljevic MD (Austria) / All FacultyChair: M. Peck-Radosavljevic, MD Faculty: Marcia Simpson Brose, MD; PhD, Bruno Daniele, MD, PhD; Rodolfo Sacco, MD, PhD